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Abstract
Background: The prognosis for young people diagnosed with diabetes during childhood remains
poor and this is mainly related to the long-term risk of developing vascular complications.
Microalbuminuria identifies subjects at risk for diabetic nephropathy (DN) and cardiovascular
disease (CVD). It is often detected in adolescence but is rarely treated before the age of 18 years,
as at the end of puberty albumin excretion may decline and in some subjects will return into the
normal range. However, evidence indicates that subjects with both transient and persistent
microalbuminuria have experienced renal damage during puberty and thus reno-protection to
prevent long-term complications is warranted. In adults with diabetes and microalbuminuria, the
use of angiotensin converting enzyme inhibitors (ACEI) and Statins is increasing, and in order to
determine whether these agents are of value in the adolescent population a large randomized
controlled clinical trial is needed.
Methods/Design: The Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT) is a
multi-center, randomized, double-blind, placebo-controlled trial of ACEI and Statin therapy in
adolescents with type 1 diabetes. 500 high-risk adolescents, defined on the basis of their albumin
excretion, are randomized to receive either ACEI (Quinapril) or Statins (Atorvastatin) or
combination therapy or placebo for 3-4 years. There will also be a parallel open observational
study, based on the follow-up of 400 low-risk non-randomized adolescents. The major endpoint of
the study is the change in albumin excretion; secondary endpoints include markers of CVD, renal
function, retinopathy, quality of life combined with assessment of compliance and potential health
economic benefits.
Discussion:  AdDIT will provide important data on the potential renal and cardiovascular
protective effects of ACEI and Statins in high-risk adolescents. Long-term follow-up of the
randomized subjects will provide direct evidence of disease outcomes, in addition to the data on
early surrogate measures of DN and CVD. Follow-up of non-randomized low-risk subjects will
determine the potential impact of intervention on DN and CVD. AdDIT will help to determine
whether, in addition to encouraging young people to achieve good glycaemic control,
pharmacological cardio-renal protection should also be implemented.
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Background
Prognosis and complications of Type 1 Diabetes
The prognosis for childhood-onset type 1 diabetes (T1D)
remains generally poor [1,2] and although life expectancy
has increased by several years, reflecting increased longev-
ity in the general population, the number of life years lost
has remained unchanged over the last four decades and is
about 17 years for a child diagnosed at the age of 10 years
[3]. A recent study from Norway indicated that childhood-
onset T1D is associated with a four-fold increase in the
overall standardized mortality rate (SMR) [4], reflecting
similar data from the USA [3]. By the age of 20 to 39 years
the SMR for coronary heart disease in the British Diabetic
Association Cohort of 23,000 patients diagnosed aged less
than 30 years was increased ten-fold for men and forty-
fold for women [2]. In the second decade after diagnosis
diabetic nephropathy (DN) accounts for around 60% of
deaths, whereas by the third decade cardiovascular disease
(CVD) accounts for two thirds of all deaths [5]. However
patients with nephropathy have approximately a forty-
fold increased mortality from CVD [6]. The morbidity and
mortality in childhood-onset diabetes is overwhelmingly
associated with the development of long-term microvas-
cular and macrovascular complications. Although com-
plications are rarely seen during childhood, there is
evidence that their pathogenesis begins soon after diagno-
sis and accelerates during puberty [7,8]. Thus, adolescence
may be a critical period for lifetime risk of complications
in childhood onset T1D.
Seeds of future complications in adolescence
Glycated hemoglobin levels (HbA1c) during puberty are
invariably higher than levels recommended for preven-
tion of complications. In the Diabetes UK National Audit
the mean HbA1c in those aged under 16 years was 8.9%
and only 72% had an HbA1c less than 9.5% [9]. In the
Diabetes Control and Complications Trial (DCCT),
although adolescents showed the same benefits from
intensified therapy as adults, HbA1c levels were generally
1% higher and excess weight gain and hypoglycaemia
were more frequent in the adolescents [10,11].
It is during puberty that the first signs of complications
become evident and microalbuminuria (MA), an early
risk marker for DN and CVD [12,13] may be found in 12-
16% of adolescents [13-17]. This has been associated with
renal pathology indicative of early nephropathy [18]. The
relationship between puberty and MA is only partly
explained by poor glycaemic control and there is evidence
that puberty itself may be an independent risk factor
[13,19]. The development of MA is associated with hyper-
lipidemia [20,21], elevation of arterial blood pressure
[22], decline in renal function [23] and retinal changes
[24]. It has been suggested that MA represents the first evi-
dence of a generalized endotheliopathy [25]. Flow medi-
ated dilation (FMD), an established marker of endothelial
function, may be abnormal in adolescents with T1D [26]
and carotid artery intima-media thickness (cIMT), a
marker of early atherosclerosis and a strong predictor of
future vascular events [27], has been found to be increased
in adolescents with T1D [26,28-32]. Markers of sub-clini-
cal atherosclerosis, including cIMT, have been linked to
the development of MA in the general adult population
[33]. Markers of endothelial dysfunction and arterial stiff-
ness have also been associated with MA in diabetic popu-
lations [34,35]. Thus rapid growth and poor glycaemic
control during adolescence both contribute to the future
complications risk associated with MA.
Intervention in adolescents to prevent future 
complications
It has been argued that early intervention in adolescents
with MA is unnecessary as it may revert to normal at the
end of puberty in 50% of patients [36-40] and only
around 15% will progress to clinical proteinuria. Recent
data from the Oxford Regional Prospective Study (ORPS),
which has been following an incident cohort of around
500 children since 1986 [13,41], indicate that MA is tran-
sient in 39% and with continued follow up, 48% of sub-
jects have persistent MA and 13% have intermittent MA.
4% of the ORPS cohort has developed clinical proteinuria
and this is related to both persistent (hazard ratio (HR):
27.7) and intermittent MA (HR 8.8) [41]. The cumulative
probability of developing clinical proteinuria was 13.9%
after 18 years diabetes duration in this population, diag-
nosed at 9.5 years [41] compared with a rate of 14.6% in
the only adult incident cohort after a similar duration of
diabetes [42]. Risk for MA can be identified by greater
rates of albumin excretion, although still within the nor-
mal range, as early as one year from diagnosis [43] and we
have recently shown that albumin excretion in the highest
tertile after adjustment for age, gender, duration of disease
and age of diagnosis, at age 11-15 years, predicts 85% of
subjects who go on to develop MA and all of the subjects
who develop clinical proteinuria [44]. Therefore early
abnormalities in albumin excretion during adolescence
are predictive of complications risk and early intervention
in high-risk adolescents could lead to long-term improve-
ments in prognosis.
Previous interventions with ACEI and Statins
T1D adults with both intermittent and persistent MA are
increasingly being treated with angiotensin converting
enzyme inhibitors (ACEI) or angiotensin receptor block-
ers (ARB), as these drugs have been shown to reduce risk
of progression of MA to clinical proteinuria and may also
be effective in reducing mortality from CVD [45]. Screen-
ing for MA is routinely recommended during adolescence
[46,47], yet recommendations for treatment are not con-
sistent. Four small studies have confirmed the likely effi-BMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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cacy of ACEI in adolescents with MA, but there have been
no formal randomized controlled trials (RCTs) [48-51]. In
a review of 12 adult trials of ACEI, reductions in albumin
excretion rates of 50.5% (95% CI: 29.2-65.5) [52] were
similar to those observed in the adolescent studies: 41%
[48] and 55-60% [49]. In the study reported by Rudberg
[53], reductions in albumin excretion were associated
with improvement in renal biopsy changes in young
patients with T1D. A beneficial effect of ACEIs treatment,
has also been demonstrated for diabetic retinopathy [54].
The EURODIAB Controlled Trial of Lisinopril in T1D
showed a significant effect of lisinopril in reducing by
around 50% the progression of retinopathy in normoten-
sive and normo- or microalbuminuric patients [54]. In the
recent Renin-Angiotensin System Study, treatment with
either enalapril or losartan reduced progression of retin-
opathy by 65-70% [55].
Hyperlipidemia is commonly reported in adolescents
with T1D [20,21] but there have been no studies of statin
therapy in this population. Treatment with HMG-CoA
reductase inhibitors (Statins) is becoming increasingly
common in adults as they reduce major vascular event
rates by about one third in T1D subjects aged > 40 years
[56]. The National Institute for Health and Clinical Excel-
lence guidelines recommend statin treatment for T1D
adults with MA or two or more features of the metabolic
syndrome and the recent Joint British Societies' Guide-
lines [57] recommend statin treatment in adults with per-
sistent MA. Management depends on extrapolating from
the results of trials conducted in adults with diabetes [58]
and short-term trials of up to two years duration con-
ducted in children with familial hypercholesterolemia
(FH) that show treatment to be efficacious and safe
[59,60]. Longer-term trials in children and adolescents
with T1D are therefore urgently needed to address clinical
uncertainty [61].
Clinical trials may need to use surrogate endpoints and
non-invasive vascular assessment techniques have dem-
onstrated abnormalities in T1D in early childhood
[26,28-32,62]. In particular, cIMT has been shown to be
significantly greater in children with T1D than in age-
matched controls [26] and not dissimilar to that observed
in heterozygote subjects with FH [63]. Other measures of
CVD risk and endothelial dysfunction, such as FMD, may
precede changes in cIMT within the first decade of T1D in
children [26] and other measures such as endothelial
pulse amplitude tonometry (EndoPAT) may also distin-
guish T1D from healthy subjects [64-66]. Arterial stiffness
as assessed by pulse wave velocity (PWV) may be an addi-
tional marker of CVD, which has been shown to be abnor-
mal in T1D patients as young as 10 years [67]. Statin
treatment would be expected to slow the progression or
result in regression of cIMT, and a two-year RCT of prav-
astatin in 214 children with heterozygous FH found active
treatment to result in a significant difference in the mean
change in cIMT between the two groups [68]. In addition
to reducing the risk of CVD, statin therapy may also
reduce the risk of nephropathy. Low density lipoprotein
(LDL) cholesterol, and small dense LDL in particular, pro-
duce proliferative and biosynthetic responses in glomeru-
lar cells that occur in the early stages of DN [69].
Mesangial cells can take up both native and modified LDL
and respond in vitro by proliferation, production of
chemo-attractants for monocytes and macrophages, and
alterations to matrix turnover leading to net matrix expan-
sion [70]. Furthermore, diabetes induced mesangial
expansion has been shown in animal models to be
reduced in a dose dependent manner by statins [71]. Sta-
tin treatment is associated with a significant reduction in
mean serum creatinine concentration [72] and a recent
trial of subjects with diabetes reported a reduction of 11%
in patients randomized to atorvastatin for three years
whilst patients randomized to standard care showed a 5%
increase in creatinine [73]. These findings suggest that sta-
tin therapy in T1D may reduce the risk of both DN and
CVD. Dyslipidemia has also been implicated in the patho-
genesis of retinopathy and consequently statin treatment
may be beneficial in limiting this complication [74,75].
Combination therapy with a statin and an ACEI for
patients at high risk of development of MA may therefore
represent the most effective strategy for reducing future
morbidity and mortality from DN and CVD in patients
with childhood-onset T1D. Thus both ACEI and Statin
therapy could provide cardio-renal protection in high-risk
subjects during adolescence and we plan to explore this
hypothesis through a randomized controlled trial.
Aim Of The Study
To carry out a multi-center, randomized, double-blind,
placebo-controlled trial of ACEI and Statin therapy in
adolescents with T1D. 500 adolescents at high risk for DN
and CVD will be randomized to receive either ACEI or
Statins or combination therapy or placebo for three to
four years (Study 1). There will also be a parallel open
observational study, based on the follow-up of 400 low-
risk non-randomized adolescents (Study 2).
1. Randomised Controlled Clinical Trial 
(Study 1)
Study Objectives
Primary
To determine whether intervention with ACEI, Statins, or
combination therapy when compared with placebo, in a
2 × 2 factorial design over three to four years, will: 1)
reduce albumin excretion as assessed by six monthly
measurement of albumin/creatinine ratio (ACR) in 3 early
morning urines; 2) reduce the incidence of MA (ACR >3.5
mg/mmol (males) or >4 mg/mmol (females) in 2 out of
3 urines) at the end of the study period; 3) reduce the inci-BMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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dence of MA during the six month run-out period follow-
ing the completion of intervention phase.
Secondary
To determine the effects of the intervention on: 1) changes
in cIMT; endothelial function and arterial stiffness; 2)
changes in arterial blood pressure (BP), blood lipids and
lipoproteins; 3) changes in glomerular filtration rate
(GFR) as assessed by plasma symmetric dimethylarginine
(SDMA), creatinine and cystatin C levels; 4) changes in
CVD risk markers: high-sensitivity C-reactive protein
(hsCRP) and asymmetric dimethylarginine (ADMA); 5)
incidence of retinopathy and subclinical changes in the
retinal microvasculature; 6) quality of life, risk benefit,
compliance and health economic assessment; 7) long-
term outcomes with regard to incidence of DN and CVD.
Study endpoints
The primary endpoint is defined as the area under the
curve over time of log ACR per year, with standardization
for gender, age and duration of diabetes.
The secondary endpoints are: 1) changes in cIMT, FMD,
EndoPAT and PWV between baseline and the end of inter-
vention period; 2) changes in arterial BP, lipids and other
lipoproteins, CVD risk markers (hsCRP and ADMA),
assessed every 6 months during the intervention period;
3) changes in measures of GFR (plasma SDMA, creatinine
and cystatin C) assessed every 6 months during the inter-
vention period; 4) changes in retinopathy scores and reti-
nal microvascular structure (arteriolar or venular dilation,
vascular fractal dimension, branching and tortuosity),
assessed annually; 5) changes in quality of life and health
economics.
Methods/Design
Design of the RCT
The study is a multicenter randomized trial involving
centers in the UK, Australia and Canada (see additional file
1).
Subjects will be recruited from a pre-screened population
of ~3,000 young people with T1D aged 11 to 16 years
based on assessment of risk for future CVD and DN. Sub-
jects deemed to be at high risk, based on their albumin
excretion rate, will be randomized to a 2 × 2 factorial
design contrasting the effects of ACEI, statins, or combina-
tion therapy to placebo over a three to four year treatment
period. Minimization of variation between study arms in
albumin excretion rate, gender, age, diabetes duration,
HbA1c, total cholesterol and center location will be
undertaken at randomization.
Analysis of the primary endpoint, change in albumin
excretion, will be undertaken on an 'intention to treat'
basis. Secondary analyses will be undertaken on the basis
of 'as treated' allowing for variance in compliance and
allowing for subjects who show substantial changes in
HbA1c levels. Additional analyses will be undertaken to
assess changes in the secondary objectives and to assess
the overall effect of the intervention on quality of life and
health economics.
Study population for the RCT
• Definition of high-risk subjects
Subjects with T1D within the age range 11-16 years are
screened in the UK, Australia and Canada to determine
the ACR in two sets of 3 early morning urines. The defini-
tion of a high-risk subject is based on previous data
derived from the ORPS and Nephropathy Family Study
(NFS) cohorts [41,76].
Preliminary data from the ORPS cohort (1,697 sets of
urines from 479 subjects) indicated that the log standard-
ized ACR based on the residuals from a regression model
of log ACR adjusted for age, gender, age at diagnosis and
duration of diabetes at 11-15 years was highly predictive
of risk for the development of MA [44]. The average resid-
ual across visits provided a robust estimate of standard-
ized ACR and a value above the cut-off point of 1.2
defines the high-risk upper tertile. A validation of the
applicability of the ORPS ACR cut-off point and regres-
sion coefficients to another cohort was conducted in 690
subjects aged 11-15 years with ACR measures from two
sets of 3 urines in the NFS. 27.5% had standardized ACR
values in the top tertile; 93% of those selected using the
ORPS coefficients and cut-off point would also have been
selected with revised coefficients. This indicates good
reproducibility, in a context where the mean HbA1c was
1% lower in the NFS when compared with the ORPS
cohort.
During screening for AdDIT, two mean ACR measures,
each based on three early morning samples, will have
been provided by a subject. These will be averaged on the
log ACR scale and the subject's average residual will be cal-
culated using gender, age and duration and the coeffi-
cients from the ORPS linear regression model. If the
subject's residual lies above log 1.2 the patient will lie in
the upper tertile indicating high risk and eligibility for the
trial.
Inclusion criteria
1) Age 11 to 16 years; 2) T1D diagnosed for more than 1
year or C-peptide negative; 3) Centralized assessment of
ACR based on six early morning urines deemed to be in
upper tertile for risk after adjustment for age, gender, age
at diagnosis and duration of disease.BMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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Exclusion Criteria
the presence of any of the following will prevent patient
inclusion: 1) Non T1D, i.e. type 2 diabetes, insulin
dependent diabetes related to monogenic disease, second-
ary diabetes; 2) ACR based on six early morning urines
deemed to be at low risk for subsequent development of
CVD or DN; 3) Pregnancy or unwillingness to comply
with contraceptive advice and regular testing throughout
trial; 4) Breast feeding; 5) Severe hyperlipidaemia and
family history data to support diagnosis of familial hyper-
cholesterolaemia; 6) Established hypertension unrelated
to DN; 7) Prior exposure to the investigational products;
8) Unwillingness/inability to comply with the study pro-
tocol; 9) Other co-morbidities considered unsuitable by
the investigator (excluding treated hypothyroidism and
celiac disease); 10) Proliferative retinopathy.
￿ Sample size determination and power calculations
Number of Subjects required
The primary power calculation estimates that 400 subjects
will need to be analyzed and we aim to recruit 500 to
allow for dropouts and non-compliance.
Power calculations based on the primary endpoint
A 30% reduction in ACR is considered a worthwhile and
plausible effect size to detect in this population and detec-
tion of a 25% reduction would be an advantage. With the
2 × 2 factorial design we plan for follow-up of 100
patients in each of the four arms: Placebo (P), ACEI (A),
Statin (S), combination of ACEI and Statin (C). This sam-
ple size is informed by the ORPS cohort study (477 partic-
ipants in the correct age range of recruitment with a mean
of 3.5 observations over time) [13]. Within the tertile with
the highest ACR standardized for gender, age and dura-
tion (defined as standardized ACR > 1.2), the standard
deviation (SD) of standardized log to base 10 of ACR was
0.38 (mean 0.28) based on analyzing the final value
alone, whereas the SD of the average standardized log
ACR repeated over time, defined as area under curve per
year, was 0.28 offering a reduction in detectable effect size
from 30% to 25%. The primary endpoint is therefore
defined as area under curve of log standardized ACR, with
standardization for gender, age and duration of disease.
The chosen sample size and endpoint provide 93% power
to detect a 25% reduction in ACR attributable to the fac-
torial main effect of ACEI (A and A+S arms [n = 200 total]
versus P and S arms [n = 200 total]), and of Statin (S and
S+A arms [n = 200 total] versus P and P+A [n = 200 total]).
Additionally there is 82% power to detect a 30% reduc-
tion in ACR, in the following single-arm comparisons: A
[n = 100] versus P [n = 100]; S [n = 100] versus P [n = 100];
and S+A [n = 100] versus P [n = 100].
Power calculations for secondary endpoints
For secondary outcomes, a 1% level of significance will be
applied. For continuous outcomes, the sample size allows
detection of small to moderate effect sizes; there will be
82% power in single arm comparisons to detect effect
sizes of 0.5 SD between arms, and 93% power for factorial
main effects of size 0.4 SD. For the secondary outcome
cIMT, a pooled estimate across two studies of the SD of
change from baseline is 0.044 [68]. There is 93% power to
detect a 0.018 mm difference for ACEI and Statin factorial
main effects, and 82% power to detect a 0.022 mm differ-
ence for single-arm comparisons.
For the secondary outcome FMD, an estimate across
recent studies of the SD of change from baseline is 2.5.
180 subjects will give 80% power to detect a 1.5% differ-
ence in FMD between baseline and final assessment at a
5% level of significance.
For the secondary outcome PWV, an estimate across
recent studies of the SD of change from baseline is 1.5.
200 subjects will give 80% power to detect a 0.85 m/sec
difference in PWV between baseline and final assessment
at a 5% level of significance.
For the secondary outcomes retinopathy and subclinical
changes in the retinal microvasculature, the sample size
will give greater than 90% power to detect a 25% differ-
ence in retinopathy prevalence and to detect a minimum
of 3% change in retinal vascular parameters.
For binary outcomes, the sample size allows detection of
moderate to large difference in proportion effect sizes,
when the proportion is the mid-range of 0.2 to 0.8; so that
there is 93% power to detect factorial main effects of a
50% relative reduction for proportions 0.4 versus 0.2, and
the corresponding relative reduction detectable for the
single-arm comparisons is 58%. For the secondary out-
come of MA over the two measurements at age 18, the
detectable reduction for factorial main effects is prohibi-
tively large, 75%, due to a necessarily low prevalence in
the treated arm, and therefore the more sensitive continu-
ous ACR outcome will be the primary indicator of MA.
Study procedures (Figure 1)
Recruitment
Eligible subjects and their families will be approached by
the research nurse and the local principal investigator (PI)
and they will be provided with a verbal explanation of the
study and written information sheets. Once they have
been given sufficient time to consider their participation
in the trial, the parents will be asked to provide written
informed consent and children to provide evidence of
their assent to the study procedures.BMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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Combined study flow-chart Figure 1
Combined study flow-chart.BMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
Page 7 of 18
(page number not for citation purposes)
Baseline Assessment
Once consent has been obtained, baseline assessments
will be undertaken within 3 months of recruitment. These
will include measurement of height, weight, waist circum-
ference (WC), arterial BP and assessment of pubertal
stage. Blood samples will be taken for measurement of
HbA1c, total cholesterol, triglycerides, HDL-cholesterol,
LDL-cholesterol, lipoproteins, SDMA, creatinine, cystatin
C, CVD markers (hsCRP and ADMA) and DNA extraction.
All subjects will also have alanine aminotranferase (ALT)
and urea and electrolytes (U&E) assessed locally and post-
menarchal sexually active girls will have pregnancy tests.
All subjects will be asked to attend designated centers for
cIMT assessment and, where facilities allow, also FMD,
EndoPAT and PWV. They will be asked to complete a sim-
ple quality of life questionnaire and a short questionnaire
for Health Economic analysis. Anonymised digital copies
of the most recent retinal photographs, performed as part
of the routine annual screening, will be also collected for
centralized assessments.
Randomization
Eligible subjects who have provided informed consent
and have completed baseline assessments will be rand-
omized by the PI using a secure internet-based service
http://www.sealedenvelope.com. This provides randomi-
zation with minimization [77]. Subjects will be allocated
to one of four treatment regimens after minimizing differ-
ences between arms on the following baseline characteris-
tics: HbA1c (<7.5, 7.5-8.5, > 8.5%), log mean
standardized ACR (>1.2 to <1.7, >1.7), gender, age (11-
13, >13 years), duration of disease (<5 years, >5 years),
total cholesterol (≥ 4.46 or < 4.46 mmol/l).
Initiation of therapy
Following confirmation of patients' eligibility for the trial
they will be randomized, and intervention will com-
mence. Subjects will be instructed by the research nurse/
PI about the administration and the storage of the investi-
gational medical products (IMPs). Furthermore, the
patients and their parents will be informed about possible
side effects related to the drug and will be instructed to
report any adverse events during treatment. Contact dur-
ing the first four weeks of treatment will be maintained
weekly by the research nurse, through visits or by tele-
phone at pre-arranged times.
Treatment period assessment
Subjects will be seen two weeks after commencing treat-
ment for assessment of compliance, adverse events and
adjustment of the dose of Quinapril/Placebo. Subjects
will be seen again after one month, when toxicology tests
will be also performed (ALT and U&E). Every three
months subjects will undergo a routine clinical assess-
ment with local measurement of HbA1c. Six-monthly
assessment will include: three consecutive early morning
urines for ACR, height, weight, waist circumference,
pubertal stage, BP, smoking status, HbA1c, blood lipids
and lipoproteins, plasma SDMA, creatinine, cystatin C
and CVD biomarkers, toxicology (ALT, U&E) and preg-
nancy tests. Compliance will be assessed by return of
study drugs and drug bottles with electronic track caps.
Quality of life and health economics will be assessed
annually with a questionnaire. At each annual visit, sub-
jects will be asked whether they have undergone routine
annual retinal screening and anonymised digital copies of
retinal photographs will be collected for centralized
assessment.
Final assessment
The final assessment after 3-4 years of the intervention
will be identical to the initial assessment and will include
measurement of cIMT and, where facilities allow, FMD,
EndoPAT and PWV. Anonymised digital copies of the
most recent retinal photographs, performed as part of rou-
tine screening, will be collected for centralized assess-
ment.
Run-out assessments
At the end of the intervention period and following the
final study assessment, all study drugs will be withdrawn
and subjects will be followed for a 6-month run-out
period. At the end of this period subjects will be asked to
provide a final blood sample and three early morning
urines for assessment of ACR and MA status and measure-
ment of lipids, lipoproteins, CVD risk markers, SDMA,
creatinine and cystatin C. These data will be used to
inform physicians as to the need for re-starting IMP
according to local prescribing guidelines in subjects aged
15-19 years.
Long-term follow-up
Consent is obtained in the initial consent procedures for
possible long-term surveillance through postal question-
naires and possible recall 5 and 10 years after study initi-
ation. In the UK registration with the Office for National
Statistics (ONS) may also be sought.
Investigational Medical Products (IMPs)
The active drugs (Atorvastatin and Quinapril) will be
manufactured by Pfizer, along with appropriate placebos
with adherence to Good Manufacturing Practices. Atorv-
astatin will be provided in a single dose of 10 mg daily for
oral administration with an identically labeled placebo
(Study drug A). Quinapril will be available at 2 doses: 5
mg and 10 mg with appropriately matched placebo
(Study drug Q). Subjects will be started on 5 mg and
reviewed after two weeks; if there have been no adverse
reactions in this time, the dose will be increased to 10 mg
daily, otherwise it will maintained at 5 mg. Any subjectsBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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experiencing apparent side effects (postural hypotension
or persistent cough) will have the option of changing to
the lower dose at any point during the study.
Subjects will be instructed to take two tablets per day;
Pharmacists will be instructed to dispense the blinded
product according to the schedule and advised that dose
of Study drug Q may need to be reduced. All drugs will be
given orally as tablets. No subject will be exposed to more
than 10 mg of Quinapril or 10 mg of Atorvastatin. Sub-
jects will be treated with the IMPs for a minimum of three
years and up to four years depending on age at recruit-
ment.
Both ACEI and Statins are licensed for use in children and
adolescents in the UK, Australia and Canada. However the
product licenses are related to the treatment of hyperten-
sion in non-diabetic subjects and the treatment of hyperl-
ipidaemia in subjects with familial
hypercholesterolaemia. To facilitate the use of the drugs in
children with T1D an appropriate Clinical Trial Authori-
zation has been obtained from regulatory authorities in
the UK, Canada and Australia.
The drugs and placebo will be delivered to Catalent
Pharma Solutions, the contracted distribution company
that will be responsible for packaging, labeling and distri-
bution of the IMPs to the designated pharmacies at the
study sites. Electronic pill bottle monitoring caps supplied
by AARDEX (Zug, Switzerland) will be used. These track
caps incorporate a micro-electronic circuit, which records
each opening and closing in order to track compliance.
Central pharmacies will dispense the IMPs to the study
subjects through the research nurses employed by the
local PIs. The nurses will then instruct the patients about
the proper storage and use of the drugs, including the
return of all unused tablets. IMPs will be dispensed
according to local requirements as stated in Standard
Operating Procedures (SOPs) and taking account of local
regulations.
Common adverse drug reactions have previously been
reported for Atorvastatin [78] and Quinapril [79]. For the
purposes of adverse event reporting during study visits,
particular attention will be paid to possible hyperkalemia,
persistent dry cough, hypotension, GFR decline, ALT lev-
els for liver function and muscular pain/rhabdomyolysis.
Both Quinapril and Atorvastatin are contra-indicated dur-
ing pregnancy because of concern about teratogenecity
and because they may interfere with early fetal growth and
result in stillbirth. See additional file 2 for more informa-
tion.
Blinding and Emergency unblinding
The subject, local investigator and all study and project
management staff will be blinded as to treatment alloca-
tion. Subjects will be randomized using the web-based
system and the Cambridge coordinating center will
receive notification of randomization within 24 hours.
The randomization website http://www.sealedenve
lope.com provides a facility for emergency unblinding of
drug allocation. Each PI will be provided with a password
which will allow access to their patients' treatment alloca-
tion. All emergency unbinding will be at the discretion of
the local investigator, when clinically indicated for the
safety of the patient. Unblinding will also be possible
through the pharmacy. Investigators should refer to SOPs
for the unblinding procedure. All unblindings are auto-
matically notified by email to the study-coordinating
center in Cambridge to prevent abuse of the system and to
ensure rapid notification to the data monitoring and eth-
ics committee (DMEC) of potential serious adverse events
(SAEs).
Compliance
Subject compliance will be assessed at each 3-monthly
study visit, when all unused study drug will be returned
and will be recorded in the CRFs by the research nurses.
AARDEX electronic pill bottle track caps, which permit
checks of the number of times the pill container has been
opened between study visits [80,81], will also be used.
The track cap data will be available locally through soft-
ware provided by AARDEX and can be used by the study
nurses to encourage compliance and where appropriate
introduce interventions to improve compliance. We will
also make regular contact with study subjects through
newsletters identifying the value of continued involve-
ment in the study protocol.
Withdrawal of study drugs
With exception of pregnancy, if it is deemed necessary to
withdraw a patient from one of the study drugs this will
not preclude their continuing participation in the study.
Subjects withdrawn from either of the study IMPs will be
encouraged to remain in the trial.
Rescue medications
Patients developing clinical hypertension will be treated
at the discretion of the local investigator. Treatment is ini-
tially expected to be a diuretic, followed by the use of a
calcium channel blockers (or similar agent). Very high
cholesterol levels, perhaps related to familial hypercholes-
terolaemia rather than T1D will be identified at baseline
as an exclusion criterion. However, if at any time during
the intervention period LDL cholesterol levels are found
to be above 4.6 mmol/l and/or triglyceride levels are
above 9 mmol/l, the central laboratory will notify the site.
A first attempt to reduce lipids levels will be made byBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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improving the patient's glycaemic control and dietary
intervention; a second lipid measurement will be per-
formed within four weeks. If the second value is still
above the threshold, the case will be notified to the DMEC
for consideration of withdrawal from the study. If at any
time during the study, the ACR is in the macroalbuminu-
ric range (ACR>35 mg/mmol in males and >47 mg/mmol
in females [13]), these cases will be notified to the DMEC
for consideration of withdrawal from the study
2. Study 2: Follow-Up Of Non-Randomised Low 
Risk Subjects
Study objectives
The primary objective of Study 2 is to determine the rela-
tionship between albumin excretion and cIMT both at
baseline and after 3-4 years in subjects deemed to be at
low risk on the basis of urinary albumin excretion when
aged 11-16 years.
The secondary objective is to determine the relationship
between albumin excretion and changes between baseline
and 3-4 years in: 1) additional measures of subclinical
atherosclerosis, such as endothelial function and arterial
stiffness; 2) CVD risk markers: hsCRP and ADMA; 3) arte-
rial BP, blood lipids and lipoproteins; 4) GFR as assessed
by SDMA, creatinine and cystatin C levels; 5) long-term
outcomes with regard to incidence of DN and CVD.
Study endpoints
The primary endpoint is the relationship between ACR
and cIMT and how this changes during puberty.
The secondary endpoints are: 1) changes in FMD,
EndoPAT, PWV between baseline and the end of the
study; 2) changes in arterial BP, lipids and other lipopro-
teins, CVD risk markers (hsCRP and ADMA), assessed
annually; 3) changes in measures of GFR (plasma SDMA,
creatinine and cystatin C), assessed annually; 4) changes
in retinopathy scores and in the retinal microvasculature
(arteriolar or venular dilation, vascular fractal dimension,
branching and tortuosity), assessed annually.
Method/Design
Study design
This will be an open observational study of low-risk sub-
jects in the UK. In the UK, 400 subjects not recruited into
the interventional study (from the medium and low ter-
tiles of ACR) will be assessed at baseline with measure-
ment of cIMT (and FMD, EndoPAT and PWV where
facilities allow), BP, lipids, HbA1c, and CVD markers and
renal function. Copies of the most recent digitalized reti-
nal photographs, performed as part of the annual routine
screening, will also be collected and retained for central-
ized assessments. These subjects, together with 200 high
risk individuals in the UK from the RCT will form the
cohort of 600 subjects to enable the study of the relation-
ship between markers of sub-clinical atherosclerosis
(cIMT, endothelial function and arterial stiffness), and
albumin excretion and its modification by cardiovascular
risk factors, renal function and diabetes control. 200 of
the low risk subjects will be re-assessed annually and 3-4
years after initial screening. The findings will be compared
to treated subjects from the interventional trial including
100 high risk subjects randomized to placebo arm. The
aim is to provide additional data concerning the natural
history of renal, cardiac and retinal measures in subjects
deemed to be at different levels of risk.
Study population
￿ Definition of low-risk subjects
As in the RCT, during the screening phase of the study two
ACR measures, each based on three early morning urine
samples, are to be provided by a subject. These will be
averaged on the log ACR scale and the subject's average
residual will be calculated using gender, age, age at diag-
nosis and duration of diabetes, as well as the coefficients
from the ORPS linear regression model. If the subject's
residual lies below log 1.2 the patient will lie in the
medium or lower tertile indicating low risk and eligibility
for the non-randomized study.
￿ Inclusion and exclusion criteria
Inclusion criteria
1) Age 11 to 16 years; 2) T1D diagnosed for more than 1
year or C-peptide negative; 3) Centralized assessment of
ACR based on six early morning urines deemed to be in
middle or lower tertiles for risk after adjustment for age,
gender, age at diagnosis and duration of disease.
Exclusion Criteria
The presence of any of the following will preclude patient
participation: 1) Non T1D, i.e. type 2 diabetes, insulin
dependent diabetes related to monogenic disease, second-
ary diabetes; 2) ACR based on six early morning urines
deemed to be at high risk for subsequent development of
CVD or DN; 3) Severe hyperlipidaemia and family history
data to support diagnosis of familial hypercholesterolae-
mia; 4) Established hypertension unrelated to DN; 5)
Prior exposure to the investigational products, statins and
ACEI; 6) Other co-morbidities considered unsuitable by
the investigator (excluding treated hypothyroidism and
celiac disease); 7) Proliferative retinopathy.
￿ Sample size determination and power calculations
Based on a previous pediatric cohort of 45 patients with
T1D with mean cIMT of 0.58 (SD 0.05), a sample size of
600 subjects at baseline (200 subjects evaluated per tertileBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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of ACR) would allow mean cIMT in this population to be
estimated precisely with 95% confidence interval of ±
0.004 mm and would provide 83% power to detect an
unadjusted correlation of ≥ 0.12 between cIMT and ACR
(α = 5%). This will allow sensitive detection of the associ-
ation between ACR and cIMT after adjustment for poten-
tial confounders (such as age, gender, blood pressure,
lipids, inflammation and HbA1c) using multiple linear
regression.
For the analysis including data from baseline and at the
end of the study, 300 subjects (100 high risk subjects from
the RCT plus 100 low risk subjects from the middle and
lower tertiles of ACR), the study will provide 80% power
to detect correlation coefficients, such as between cIMT
and ACR ≥ 0.16 (α = 5%). Assuming the same standard
deviation of 0.044, analysis of the trend in cIMT across all
three tertiles of ACR allows a range of ≥ 0.035 mm in
mean cIMT to be detected across tertiles, and ≥ 0.022 mm
between two tertiles. The analysis will include a regression
model incorporating the 600 cIMT measures from sub-
jects where cIMT was measured at both baseline and fol-
low-up, to estimate the shape of progression of cIMT by
gender and age over time and in relation to puberty and
other potentially predictive characteristics.
For FMD, an estimate across recent studies of the SD of
change from baseline is 2.5. 70 subjects will give >90%
power to detect a 1% difference in FMD between baseline
and final assessment at a 5% level of significance. For
PWV, an estimate across recent studies of the SD of change
from baseline is 1.5. 95 subjects will give 90% power to
detect a 0.5 m/sec difference in PWV between baseline
and final assessment at a 5% level of significance.
Study Procedures (Figure 1)
Recruitment
Eligible subjects and their families will be approached by
the research nurse and the local PI and they will be pro-
vided with a verbal explanation of the study, and written
information sheets. Once they have been given sufficient
time to consider their participation in the trial, the parents
will be asked to provide written informed consent and
children to provide evidence of their assent to the study
procedures.
Baseline assessment
Once consent has been obtained, baseline assessments
will be undertaken within 3 months of recruitment. These
assessments will include: cIMT (and FMD, EndoPAT and
PWV where facilities allow), blood samples for lipids and
lipoproteins, CVD risk markers, SDMA, creatinine, cysta-
tin C, three early morning urines for ACR and collection
of anonymised digital copies of the most recent retinal
photographs, performed as part of the annual routine
screening, for centralized assessments. These subjects will
also be asked to complete annual questionnaires regard-
ing quality of life and to provide data for economic assess-
ments during the study period. It is anticipated that 200 of
these subjects will agree to the assessment of ACR (3
urines), blood tests and cardiovascular assessments and to
retain copies of their retinal photographs for centralized
assessment at the end of the study period. This will pro-
vide additional data concerning the natural history of
these markers of complications risk. These 200 subjects
will be asked to consent to long-term follow up and re-
assessment five years after the end of the study period.
Follow-up assessments
As routine, subjects will be seen quarterly in clinics with
local assessment of HbA1c to facilitate appropriate medi-
cal care and where appropriate intensification of insulin
therapy. Height, weight, waist circumference and arterial
BP will also be assessed at each visit.
Every 6 months, three early morning urine samples will be
collected for centralized analysis of the ACR. Pubertal
stage and smoking status will also be assessed.
Annually, blood samples will be taken for lipids and lipo-
proteins, CVD risk markers, SDMA, creatinine, cystatin C
and subjects will also be asked to fill in a questionnaire to
provide control data for quality of life and health eco-
nomics assessment of the intervention cohort. Ano-
nymised digital copies of the most recent retinal
photographs, performed as part of the annual routine
screening, will be collected and retained for centralized
assessment.
Long-term follow up of screened and intervention cohort (Study 1 
and Study 2)
The primary and secondary outcomes of the study are
robust, but they are surrogates for long-term DN and CVD
risk. It is therefore essential that planned follow-up of the
cohort is undertaken. In the UK all of the subjects, both
randomized and non-randomized controls will be flagged
by the UK Office for National Statistics (ONS) in order to
track them through the UK National Health Service data-
base and to permit tracing and outcome assessment by
local consultants and to receive notifications of deaths.
We will undertake similar tracking of subjects in Canada
and Australia using national health numbers and diabetes
registers.
In addition we plan formal re-assessment of all rand-
omized (400) and non-randomized subjects (UK 200)
five years after the end of the study, subject to successful
completion of the study and securing further funding.
This assessment would include cIMT (and FMD, EndoPAT
and PWV where facilities allow) and markers of CVD riskBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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combined with a comprehensive assessment of microvas-
cular complications including urinary albumin excretion,
GFR and retinal photographs. To facilitate this long-term
follow-up we will endeavor to keep in touch with the
cohort through annual newsletters.
3. Common Methods For Study 1 And Study 2
Data management
At screening, all subjects are given a unique identifying
number which will be translated into a barcode used for
all subsequent correspondence, transfer of samples and
data input to the centralized database. Study databases are
developed "in house" and incorporate quality control
(QC) checks to ensure accurate data entry data. Standard-
ized CRFs have been developed for use in all centers.
Results from the Central Laboratory for screened subjects
will be available on a secure website in order to identify
those eligible for recruitment and randomization.
Data from the CRFs will be entered onto a secure locally
held database at each center with anonymised data regu-
larly sent to the central database held at the Clinical Trials
Unit in Cambridge. Off line checks will be run on data
received to identify missing or inaccurate data and queries
will be fed back to centers using existing SOPs. A random
10% of CRFs from each center will be double data entered
by staff in Cambridge to provide an additional QA check.
Laboratories
The WellChild laboratory at The Evelina Children's Hos-
pital, London will undertake centralized assessments of
all urinary screening samples, 6 monthly study urine sam-
ples and bloods for HbA1c, creatinine, SDMA, cystatin C,
fasting lipids, lipoproteins, ADMA, and hsCRP. Urine
albumin will be measured using laser immunonephelom-
etry (Dade Behring) and for concentrations <2.1 mg/l by
an enzyme linked immunoabsorbent assay (ELISA).
Urine creatinine will be measured using a chromato-
graphic stable isotope dilution electrospray mass spec-
trometry-mass spectrometry (MSMS) method. HbA1c %
will be measured in filter paper blood spots, after endo-
proteinase Glu-C digestion, using an MSMS reference
method measuring the -N-terminal hexapeptides of
HbA1c and HbA0. GFR will be monitored using plasma
creatinine measured by a NIST traceable MSMS method
and estimated GFR (eGFR) calculated from the formula:
eGFR (ml/min/1.73 m2) = 42*height (cm)/plasma creati-
nine (μmol/l). GFR will also be monitored using plasma
SDMA, measured by MSMS, and cystatin C, measured by
laser immunonephelometry (Dade Behring); both GFR
markers are independent of body size [82-84].
CVD biomarkers will include fasting lipids and lipopro-
teins, measured using routinely available methods, hsCRP
by laser immunonephelometry (Dade Behring), and
ADMA by MSMS. Serum and plasma will be stored at -
80°C for future analysis of any compelling biomarkers.
Local site-specific laboratories will analyze toxicology
data (U&E, ALT) and pregnancy tests and details of local
methods, normal ranges, QC and QA will be obtained
during site set up visits and confirmed during monitoring
visits. 3-monthly HbA1c will be also assessed in local lab-
oratories, using DCCT aligned methods.
Cardiovascular assessments
cIMT will be assessed at baseline and the end of the study
in designated centers in the UK, Australia and Canada,
through collaborative agreements. Where facilities and
training allow, centers will also provide endothelial func-
tion assessment (by FMD and EndoPAT) and arterial stiff-
ness assessment (by PWV) at baseline and at the end of
the study.
cIMT will be quoted as end-diastolic mean-mean and end-
diastolic mean-max. The maximum IMT measurement of
a segment of arterial wall will be defined as the single
point along an approximate one-centimeter length in
which the lumen-intima and media-adventitia interfaces
are separated by the greatest distance. Several maximum
IMT measurements will be averaged to produce the mean-
max IMT. The mean IMT measurement will be defined as
the mean-mean of multiple single point IMT measure-
ments across an approximate one centimeter segment of
arterial wall. All IMT measurements will be made during
end-diastole. One arterial wall segment will be imaged,
this will be the common carotid 1 cm proximal to the dil-
atation of the bifurcation. During each ultrasound exami-
nation, the right and left common carotid arteries will be
visualized and ultrasound images recorded at a single
fixed interrogation angle. The head will be rotated to 45
degrees from the midpoint and the carotid artery scanned
in the ear-ear plain. Optimal images will be triggered on
the R-wave of the ECG and recorded in DICOM format as
still images or as a cine loop onto CD for later offline anal-
ysis in the core laboratory. Arterial diameter measure-
ments will also be recorded in order to calculate carotid
distensibility.
FMD will be measured using high resolution ultrasound
to image the brachial artery in the mid upper arm, proxi-
mal to a blood pressure cuff placed just below the antecu-
bital fossa. During each ultrasound examination, the
brachial artery will be scanned in longitudinal section and
digitized ECG-gated end-diastolic images will be
acquired. A hard copy of the B-mode brachial artery image
will be stored. Diameter will be determined using an auto-
matic edge-detection algorithm and blood flow measured
from the velocity-time integral of the Doppler signal.
Reactive hyperemia will be stimulated by inflation of aBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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blood pressure cuff to suprasystolic pressure for 5 min-
utes, followed by deflation.
The EndoPAT system (endothelium pulse amplitude
tonometry) will be used to give a measure of Reactive
Hyperemic Index (RHI), a measure of endothelial func-
tion designed to be used in conjunction with FMD meas-
urement of reactive hyperemia. The EndoPAT probe is a
finger plethysmograph. One probe, formed as a thimble,
is placed on each index finger. This probe causes a harm-
less occlusion of the finger and gives a uniform, near-
diastolic external pressure over the distal index finger. The
probes will be inflated for five minutes to record a base-
line amplitude before the FMD cuff occlusion of the fore-
arm is achieved. The FMD cuff will be inflated for five
minutes and then will be deflated. During this time the
probes on the index fingers remain inflated and will con-
tinue to remain inflated for a further five minutes after
cuff deflation. RHI is calculated by integral software.
PWV will be calculated, using measurements obtained by
the SphygmoCor system, from pulse pressure waveforms
obtained from the carotid, radial and femoral arteries. A
pressure tonometer will be placed at the site of each artery
for a few seconds until a pressure waveform is recorded
and the distance between the carotid-radial and carotid-
femoral pulse points will be measured. Integral software
calculates the pulse time delay between the points and
uses this to give a PWV measurement. All sonographers
participating in the cIMT measures will undertake specific
training directed by the core laboratory in London (UK).
Retinal assessment
Annual screening for retinopathy is routinely performed
in adolescents with T1D [46]. Anonymised digital copies
of the most recent retinal photographs will be collected
from each patient at the baseline visit and then during
each annual visit until the final assessment. These digital
photographs will be used for centralized grading of dia-
betic retinopathy and, where possible, also for detailed
study of the retinal microvasculature.
Stereoscopic fundal photography of seven standard fields
is the most sensitive detection methods, which is gener-
ally recommended and performed [85]. However, differ-
ent centers may adopt other validated methods and for
the present study, all annually performed retinal photo-
graphs with or without mydriasis will be considered. Min-
imum requirements are a pupil size after dark adaptation
of at least 4 mm and two 45-degree photographs taken of
each eye, a total of four photographs for retinopathy grad-
ing (centered on optic disc and on macula).
Diabetic retinopathy will be graded centrally accordingly
to the Early Treatment Diabetic Retinopathy (ETDRS)
adaptation of the modified Airlie House classification of
diabetic retinopathy [86]. Retinopathy levels for each eye
will be classified as follow: level 10: no retinopathy; level
21: at least one microaneurysm or hemorrhage; level 31:
microaneurysm plus one or more hemorrhage, exudate,
venous bead or loop; level 41: moderately severe non-pro-
liferative retinopathy. The level of retinopathy of the more
severely affected eye will be used for assigning the ETDRS
grade to a participant.
Digital fundus images should have enough resolution to
permit assessment of minor vessel contour. A resolution
of 6 microns/pixel or smaller is appropriate. Therefore,
where retinal photographs with an adequate resolution
and format are available, subclinical retinal microvascular
changes, including arteriolar and venular caliber changes,
altered vascular fractal dimension, branching and tortuos-
ity, will also be assessed centrally. Retinal vascular caliber
and the other vascular aspects will be assessed using a
computer program following previously validated proto-
cols [87,88].
Quality of Life and Health Economics Assessments
An economic evaluation will be conducted to estimate the
costs, effects and cost-effectiveness of each IMP and com-
bination therapy in comparison with placebo. It will con-
sist of a within-trial evaluation and a long-term cost-
effectiveness analysis using an extrapolation model to
estimate costs and outcomes beyond the end of the trial
period. Resource use data will be collected on the inter-
vention drugs and consultations and on health care use
associated with side effects and complications. Appropri-
ate information will be collected using the CRFs, coupled
with a questionnaire (see additional file 3), administered
annually throughout the study period to all 500 rand-
omized and 400 observational subjects, asking about out-
of-pocket costs, general practice, out-patients consulta-
tions and other expenses and services used. The euroQoI
EQ-5D quality of life instrument (see additional file 4) will
also be administered annually; it is widely used and
accepted in economic evaluation and permits calculations
of utility-based quality adjusted life years. Unit costs will
be collected from study centers and from national sources,
and will be combined with resource volumes to produce
an estimated cost per patient over the study period. Miss-
ing data will be dealt with using multiple imputation
techniques. Uncertainty will be handled using standard
statistical methods and the non-parametric bootstrap.
For the within-trial estimates of cost-effectiveness, effec-
tiveness will be measured using the primary endpoint uri-
nary albumin excretion. For the extrapolated cost-
effectiveness, we propose to use the most recent version of
the DCCT cost-effectiveness model [89]. This model has
been used extensively in economic evaluations of T1DBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
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[90] and is available for use by other researchers. The
nephropathy module of this model contains a set of neph-
ropathy health states into which the trial's urinary albu-
min excretion measures can readily be mapped. This will
permit long-term cardiovascular morbidity and mortality
to be estimated and thence cost per (quality adjusted) life
year gained. The model will be adapted to incorporate
trial-specific risk factors and population characteristics.
Statistical analysis
Continuous measures will be compared between groups
using analysis of covariance, whereas binary outcomes
will be compared using logistic regression. These models
will involve adjustment for the randomization stratifiers,
and for pre-randomization baseline outcomes to improve
precision. The primary endpoint was correlated with base-
line standardized ACR in the ORPS cohort (r = 0.3) indi-
cating potential improvement in precision of estimated
treatment effects. An initial test will be undertaken for
exclusion of the factorial interaction of ACEI with Statin,
with subsequent estimation of the factorial main effects of
ACEI and Statin and single-arm comparisons. Subgroup
analyses, for gender and for baseline standardized ACR
(using a median split), will be undertaken by adding an
interaction between the subgroup variable and factorial
main effects followed by estimation within subgroups.
Sensitivity analyses, such as for compliance and for raised
HbA1c, will involve analysis using the same methods but
applied omitting the relevant subjects or the relevant
observations within subjects. For the HbA1c sensitivity
analysis exclusions will be defined as those observations
following the initial occurrence of a change in HbA1c
from baseline in excess of 1%. An analysis restricted to the
initial two measurements (first year) where short-term
compliance is considered greater, will be performed and
contrasted with the later period using within-patient anal-
ysis. Missing data will be primarily handled by excluding
missing observations from analysis and secondly by mul-
tiple imputations [91] considering a contrast of both opti-
mistic and pessimistic scenarios for treatment effects.
Analyses will be on the primary basis of intention to treat,
with as treated and per protocol as secondary. All tests will
be two-tailed, and 5% and 1% significance levels will be
used for primary and secondary outcomes respectively.
Formal interim analyses have not been incorporated into
the design and analysis of the trial because the 3 to 4 year
period of follow-up per subject is long relative to the
recruitment period, and an interim analysis would detect
early improvements without informing maintenance of
any effect. The independent DMEC will determine how
regularly to review efficacy and safety regularly, based on
progressively longer mean treatment durations.
The sample size was based on consideration of statistical
power to detect a worthwhile and plausible treatment
effect. There is adequate power to detect main effects in
the factorial design and single-arm comparisons. It is
thought unlikely that a substantive interaction will exist
between ACEI and Statin as mechanisms differ, and the
estimation of the size of any interaction effect is not the
primary target of the trial. A factorial design is therefore
appropriate on grounds of no substantive interaction [92]
and interaction not being the primary target [93].
If an interaction, chance or otherwise, should arise then
the trial has the safeguard of the single-arm comparisons.
In the event of closure of one arm of the trial there would
remain adequate statistical power in the single-arm com-
parisons. A more detailed statistical analysis plan will be
developed from the protocol, incorporating guidelines for
factorial trials [92,93].
Adverse Events and Safety Reporting
Adverse event reporting, including suspected unexpected
serious adverse reactions (SUSARs), will be carried out in
accordance with applicable local regulations and study-
specific standard operating procedures. All sites involved
in the study will inform the Coordinating center (Cam-
bridge, UK) of any serious adverse events within 24 hours
so that appropriate safety reporting procedures can be fol-
lowed by the Sponsor. All adverse events judged by either
the investigator or the sponsor as having a reasonable sus-
pected causal relationship to ACEI or statins therapy qual-
ify as adverse reactions. SUSARs will be reported
according to the relevant timelines; expected side effects
will be reported in the annual safety report unless serious
enough to warrant expedited reporting.
Regular notification of adverse events will be made to the
DMEC, principal investigators, the Sponsor, Pfizer and
the regulatory authorities (UK Medicines and Healthcare
products Regulatory Agency (MHRA), Therapeutic Prod-
ucts Directorate (TPD) of Health Canada, Australian Ther-
apeutic Goods Administration (TGA)).
Ethical and regulatory issues
￿ Informed Consent
The subjects approached in the UK, Canada and Australia
have already consented to screening through centralized
assessment of ACR in three consecutive early morning
urines. All subjects participating in the RCT will sign an
assent form agreeing to the implementation of the full
intervention protocol involving the use of both active and
placebo medicinal products. As subjects will be aged 11-
16 years at recruitment, they will be unable to provide
informed consent; this will be obtained from parents or
legal guardians according to current ICH, Good Clinical
Practice and Medical Research Council guidelines. Both
children and the parents will be provided with full infor-
mation about the trial and adequate time to consider the
risk/benefits of participation in the study. On achievingBMC Pediatrics 2009, 9:79 http://www.biomedcentral.com/1471-2431/9/79
Page 14 of 18
(page number not for citation purposes)
age of consent, the children will be asked to sign forms
agreeing to their continued involvement in the study.
￿ Ethical committee review
The study protocol has been approved by the appropriate
ethical review committees in the UK, Australia and Can-
ada. The study is to be carried out in accordance with the
spirit and the letter of the Declaration of Helsinki and the
ICH Good Clinical Practice Guidelines.
￿ Procedures for safety monitoring during the trial
A steering committee has been established to oversee the
conduct of the study; a data monitoring and ethics com-
mittee (DMEC) will scrutinize the conduct of the study
and review data arising from the study in order to deter-
mine early stopping rules. SOPs for monitoring adverse
events and reactions are in place.
￿ Subject withdrawal
A subject may terminate participation in the study at any
time without necessarily giving a reason and without any
personal disadvantage. An investigator can stop the partic-
ipation of a subject after consideration of the benefit/risk
ratio. Possible reasons are: 1) serious adverse events; 2)
non-compliance; 3) technical grounds (e.g. patient moves
away); 4) early termination of the study at the request of
the steering committee;
5) pregnancy. The reasons for withdrawal will be clearly
documented in the CRF. For subjects who have with-
drawn from the study for any of the reasons identified
above, permission will be sought to use their data in an
'intention to treat' analysis and for further analyses of
long-term outcome data. If they consent to further com-
munication, long-term data collection relating to out-
comes will be undertaken.
Study timeline (figure 2)
Discussion
Adolescence is a critical period for the development of
vascular complications associated with diabetes [94].
Pubertal development is characterized by many physio-
logical changes, involving both hormonal and metabolic
processes, and these factors together with psychological
issues are frequently responsible for poor glycaemic con-
trol [94]. Treatment may be complicated by poor compli-
ance, difficulties in targeting insulin therapy and concerns
about weight gain [94].
It is during puberty that the first signs of both microvascu-
lar and macrovascular complications become evident. MA
often develops during this period of life [13-17] and rep-
resents an independent risk factor for the development of
nephropathy and for CVD [12,13]. The development of
Timeline and milestones Figure 2
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MA during puberty is often associated with elevated BP,
dyslipidemia, decline in renal function, sub-clinical
inflammation, endothelial dysfunction and evidence of
early atherosclerosis, such as increased cIMT [20-
23,25,26,29-32]. These data suggest that, in addition to
insulin therapy, intervention directed to provide cardio-
renal protection during this critical period may bring
long-term benefits in terms of morbidity and mortality.
However, although screening for MA during adolescence
is strongly recommended [46,95], there is no general con-
sensus as to how MA should be managed.
In adults with persistent MA, ACEI and Statins are increas-
ingly used based on clear evidence of their beneficial car-
diovascular and renal effects [56,96]. However, in order to
determine whether these agents are also of value in the
adolescent population, a clinical RCT is needed.
AdDIT aims to evaluate the efficacy of ACEI and Statins in
adolescents with T1D at high risk for DN and CVD, as
defined by increased albumin excretion, with the major
endpoint of the study being changes in albumin excretion
and secondary endpoints including markers of CVD, renal
function, retinopathy and early retinal microvascular
changes, as well as quality of life combined with detailed
assessment of compliance and likely health economic
benefits.
AdDIT will provide important data on the potential renal
and cardiovascular protective effects of ACEI and statins in
high-risk adolescents. As well as determining treatment
effect on early surrogate measures of DN and CVD, the
trial will incorporate long-term follow-up of the rand-
omized subjects to provide direct evidence of disease out-
comes. Follow-up of non-randomized low-risk subjects
will determine the potential impact of intervention on
long-term risk for DN and CVD. In addition, this study
will provide valuable data on tolerance and safety of this
therapy as well as data on compliance and health eco-
nomics.
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